NCT06050122: Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults with Gorlin Syndrome |
|
|
| Recruiting | 3 | 140 | Europe, US | Patidegib Topical Gel, Patidegib, IPI-926, Saridegib, SGT-610, Patidegib Topical Gel with no active patidegib, Vehicle Gel, Placebo | Sol-Gel Technologies, Ltd., Premier Research Group plc | Gorlin Syndrome | 12/25 | 12/25 | | |